作者:Scott D. Kuduk、Christina Ng Di Marco、Ronald K. Chang、Michael R. Wood、June J. Kim、Kathy M. Schirripa、Kathy L. Murphy、Richard W. Ransom、Cuyue Tang、Maricel Torrent、Sookhee Ha、Thomayant Prueksaritanont、Douglas J. Pettibone、Mark G. Bock
DOI:10.1016/j.bmcl.2006.01.112
日期:2006.5
A series of 2,3-diaminopyridine bradykinin B-1 antagonists was modified to mitigate the potential for bioactivation. Removal of the 3-amino group and incorporation of basic 5-piperazinyl carboxamides at the pyridine 5-position provided compounds with high affinity for the human B-1 receptor. (C) 2006 Elsevier Ltd. All rights reserved.